ReviewMarine drugs2010
New peptides isolated from Lyngbya species: a review.
Review in Marine drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Shared biosynthetic architectures generate diverse β-amino polyketide residues in cyanobacterial peptides.bioRxiv : the preprint server for biology · 2026Article
- Assessment and identification of bioactive metabolites from terrestrial Lyngbya spp. responsible for antioxidant, antifungal, and anticancer activities.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Recent progression on phytochemicals and pharmacological properties of the filamentous cyanobacterium Lyngbya sp.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Phycochemistry and bioactivity of cyanobacterial secondary metabolites.Molecular biology reports · 2022Review
- Virtual Prospection of Marine Cyclopeptides as Therapeutics by Means of Conceptual DFT and Computational ADMET.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Cyanobacteria-From the Oceans to the Potential Biotechnological and Biomedical Applications.Marine drugs · 2021Review
- Microorganisms as a Potential Source of Molecules to Control Trypanosomatid Diseases.Molecules (Basel, Switzerland) · 2021Review
- Cyanobacteria and Eukaryotic Microalgae as Emerging Sources of Antibacterial Peptides.Molecules (Basel, Switzerland) · 2020Review
- Influence of Low Salt Concentration on Growth Behavior and General Biomass Composition inMarine drugs · 2020Article
- Biological Activities of Cyclic and Acyclic B-Type Laxaphycins in SH-SY5Y Human Neuroblastoma Cells.Marine drugs · 2020Article
- Tutuilamides A-C: Vinyl-Chloride-Containing Cyclodepsipeptides from Marine Cyanobacteria with Potent Elastase Inhibitory Properties.ACS chemical biology · 2020Article
- Asymmetric Synthesis of the C15⁻C32 Fragment of Alotamide and Determination of the Relative Stereochemistry.Marine drugs · 2018Article
- Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.International journal of molecular sciences · 2018Review
- Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.Biochimica et biophysica acta. General subjects · 2018Review
- New Peptides Isolated from Marine Cyanobacteria, an Overview over the Past Decade.Marine drugs · 2017Review
- Discovery, Total Synthesis and Key Structural Elements for the Immunosuppressive Activity of Cocosolide, a Symmetrical Glycosylated Macrolide Dimer from Marine Cyanobacteria.Chemistry (Weinheim an der Bergstrasse, Germany) · 2016Article
- Amantelides A and B, Polyhydroxylated Macrolides with Differential Broad-Spectrum Cytotoxicity from a Guamanian Marine Cyanobacterium.Journal of natural products · 2015Article
- Apoptotic potential of C-phycoerythrin from Phormidium sp. A27DM and Halomicronema sp. A32DM on human lung carcinoma cells.EXCLI journal · 2015Article
- Cyanobacteria and cyanotoxins: from impacts on aquatic ecosystems and human health to anticarcinogenic effects.Toxins · 2013Review
- Biosynthesis of Athmu, a α,γ-hydroxy-β-amino acid of pahayokolides A-B.Tetrahedron letters · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyanobacteria of the genus Lyngbya have proven to be prodigious producers of secondary metabolites. Many of these compounds are bioactive and show potential for therapeutic use. This review covers peptides and hybrid polyketide-non-ribosomal peptides isolated from Lyngbya species. The structures and bioactivities of 50 Lyngbya peptides which were reported since 2007 are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.